GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Long-Term Capital Lease Obligation

Lonza Group (Lonza Group) Long-Term Capital Lease Obligation : $341 Mil (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Lonza Group Long-Term Capital Lease Obligation?

Lonza Group's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $341 Mil.

Lonza Group's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 ($323 Mil) to Jun. 2023 ($0 Mil) but then increased from Jun. 2023 ($0 Mil) to Dec. 2023 ($341 Mil).

Lonza Group's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($321 Mil) to Dec. 2022 ($323 Mil) and increased from Dec. 2022 ($323 Mil) to Dec. 2023 ($341 Mil).

Lonza Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for Lonza Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group Long-Term Capital Lease Obligation Chart

Lonza Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.88 236.38 321.39 323.10 341.12

Lonza Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 321.39 - 323.10 - 341.12

Lonza Group  (OTCPK:LZAGY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Lonza Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Lonza Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Lonza Group (Lonza Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
XSWX:EMMN XSWX:ARYN XSWX:ORON XSWX:BARN XSWX:BELL XSWX:GMI XSWX:HOCN XSWX:GALD TSE:2309 TMO DHR IQV IDXX A MTD ICLR ILMN WAT SHSE:603259 LH
Traded in Other Exchanges
LZAGF:USA LONN:Mexico LONNz:UK LO3A:Germany LONNE:Switzerland LONN:Switzerland
Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Website
https://www.lonza.com
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.